Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...
Study finds Hippo pathway aberrantly activated in NPH1 models, unveiling Kibra as a potential target
Nephronophthisis (NPH) is a recessive cystic kidney disease responsible for 10% to 20% of pediatric end-stage renal disease cases. NPHP1 (nephrocystin 1) is the most frequently implicated among over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback